Aptamer-based Theranostics in Oncology
Announcing a new article publication for BIO Integration journal. Cancer remains a major global health burden, necessitating innovative approaches for improved diagnosis and treatment. Aptamer-based theranostics have gained attention in the field of cancer research and treatment. Aptamers can be used as targeting ligands for the delivery of therapeutic agents to cancer cells, as well as for the detection and imaging of cancer, due to high binding affinity and selectivity. Aptamers are also being investigated as anticancer drugs. Specifically, aptamers serve as a tool for controlling protein activity via protein-protein and protein-ligand interactions. The aptamer-exosome technology improves aptamer targeting. To gather relevant data, we searched scientific databases, including PubMed/Medline, Google Scholar, Wiley, Web of Science, and Springer. Despite challenges, theranostics, environmental monitoring, biosensing, and other fields could benefit from the use of aptamer technology.
This review discusses the standard methods for producing aptamers, including green aptamers, and potential applications in diagnostics. Aptamers are useful in biotherapy and as anticancer drugs, and this article gives a thorough overview of both with examples. Aptamer-exosome technologies are also covered, aptasensors, and their diagnostic and therapeutic applications. Recent systematic evolution of ligands were investigated by exponential enrichment (SELEX) methodologies with a focus on carrier materials and technical advances, and the difficulties in creating aptamers that are more practical, highly efficient, and stable are discussed.
https://www.scienceopen.com/hosted-document?doi=10.15212/bioi-2024-0002
BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.
As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.
BIOI is now open for submissions; articles can be submitted online at:
https://mc04.manuscriptcentral.com/bioi
Please visit www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
Please visit www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
BIOI is available on the IngentaConnect platform (https://www.ingentaconnect.com/content/cscript/bioi) and at the BIO Integration website (www.bio-integration.org).
Submissions may be made using ScholarOne (https://mc04.manuscriptcentral.com/bioi).
There are no author submission or article processing fees.
Follow BIOI on Twitter @JournalBio; Facebook (https://www.facebook.com/BIO-Integration-Journal-108140854107716/) and LinkedIn (https://www.linkedin.com/company/bio-integration-journal/).
ISSN 2712-0074
eISSN 2712-0082
Jyoti Trivedi, Mohammad Yasir and Rahul K. Maurya et al. Aptamer-based Theranostics in Oncology: Design Strategies and Limitations. BIOI. 2024. Vol. 5(1). DOI: 10.15212/bioi-2024-0002
